全球慢性特发性便秘治疗市场规模、份额、趋势和成长分析报告（2026-2034）

预计慢性特发性便秘治疗市场规模将从 2025 年的 38.9 亿美元成长到 2034 年的 72.6 亿美元，2026 年至 2034 年的复合年增长率为 7.17%。

由于胃肠道疾病盛行率不断上升以及人们对现有治疗方案的认知度不断提高，慢性特发性便秘治疗市场预计将迎来显着增长。慢性特发性便秘（CIC）是一种常见疾病，其特征是排便次数减少或排便困难，这会严重影响患者的生活品质。随着医疗保健提供者寻求改善患者预后并更好地管理CIC，对泻药、处方药和饮食疗法等有效治疗方法的需求预计将会增加，从而推动该市场的强劲成长。

此外，慢性特发性便秘（CIC）治疗方法的进步正在推动市场创新。新型药物的研发，例如鸟苷酸环化酶C促效剂和5-羟色胺受体促效剂，拓展了CIC的治疗选择，为患者提供更有效、更具针对性的治疗方法。这些创新不仅改善肠道功能，还能解决便秘的潜在机制，进而提升患者的整体满意度。随着研究不断探索新的治疗方法和联合治疗，在改善患者照护和生活品质的推动下，慢性特发性便秘治疗市场预计将进一步扩张。

此外，慢性特发性便秘的治疗模式正在发生变化，越来越重视生活方式介入和预防性护理。随着医疗保健提供者认识到饮食、水补充和体能活动在慢性特发性便秘管理中的重要性，对教育资源和支持计画的需求预计将会增加。这种积极主动的方法不仅能帮助患者更好地管理自身病情，还能促进患者与医疗保健提供者之间的合作关係。随着市场的不断发展，结合创新治疗方法、病患教育和生活方式介入的综合方法将在推动未来成长方面发挥关键作用。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

• 市场谱系展望
• 绘製渗透率和成长前景图
• 价值链分析
• 法律规范
  • 标准与合规性
  • 监管影响分析
• 市场动态
  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 市场问题
• 波特五力分析
• PESTLE分析

4. 全球慢性特发性便秘治疗市场（依类型划分）

• 市场分析、洞察与预测
• 正常传输型便秘
• 延迟性便秘
• 其他的

5. 全球慢性特发性便秘治疗市场（依治疗方法）

• 市场分析、洞察与预测
• 药物治疗
• 非药物疗法

6. 全球慢性特发性便秘治疗市场（依治疗类型划分）

• 市场分析、洞察与预测
• 药物
• 外科手术

7. 全球慢性特发性便秘治疗药物市场

• 市场分析、洞察与预测
• 血清素 4 (5-HT4) 受体促效剂
• 鸟苷酸环化酶C促效剂
• 泻药
• 刺激性泻药
• 其他的

8. 全球慢性特发性便秘治疗市场（依给药途径划分）

• 市场分析、洞察与预测
• 口服
• 注射

9. 全球慢性特发性便秘治疗市场（以最终用户划分）

• 市场分析、洞察与预测
• 医院
• 居家照护
• 专科诊所
• 其他的

10. 全球慢性特发性便秘治疗市场（依通路划分）

• 市场分析、洞察与预测
• 医院药房
• 零售药房
• 其他的

第十一章 全球慢性特发性便秘治疗市场（按地区划分）

• 区域分析
• 北美市场分析、洞察与预测
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲市场分析、洞察与预测
  • 英国
  • 法国
  • 德国
  • 义大利
  • 俄罗斯
  • 其他欧洲国家
• 亚太市场分析、洞察与预测
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 东南亚
  • 其他亚太国家
• 拉丁美洲市场分析、洞察与预测
  • 巴西
  • 阿根廷
  • 秘鲁
  • 智利
  • 其他拉丁美洲国家
• 中东和非洲市场分析、洞察与预测
  • 沙乌地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中东和非洲国家

第十二章 竞争格局

• 最新趋势
• 公司分类
• 供应链和销售管道合作伙伴（根据现有资讯）
• 市场占有率和市场定位分析（基于现有资讯）
• 供应商格局（基于现有资讯）
• 策略规划

第十三章：公司简介

• 主要公司的市占率分析
• 公司简介
  • ALLERGAN
  • Mallinckrodt Plc
  • Synergy Pharmaceuticals Inc
  • Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Zydus Cadila
  • Boehringer Ingelheim International GmbH
  • Shreya Life Sciences Pvt Ltd
  • Abbott
  • GSK Plc
  • Troikaa Pharmaceuticals Ltd
  • Lupin
  • East West Pharma
  • Ironwood Pharmaceuticals Inc

The Chronic Idiopathic Constipation Treatment Market size is expected to reach USD 7.26 Billion in 2034 from USD 3.89 Billion (2025) growing at a CAGR of 7.17% during 2026-2034.

The chronic idiopathic constipation treatment market is poised for significant growth, driven by the increasing prevalence of gastrointestinal disorders and the rising awareness of available treatment options. Chronic idiopathic constipation (CIC) is a common condition characterized by infrequent bowel movements and difficulty in passing stools, which can significantly impact patients' quality of life. As healthcare providers seek to improve patient outcomes and enhance the management of CIC, the demand for effective therapies, including laxatives, prescription medications, and dietary interventions, is expected to rise, positioning this market for robust expansion.

Moreover, advancements in treatment options for CIC are driving innovation within the market. The development of novel pharmacological agents, such as guanylate cyclase-C agonists and serotonin receptor agonists, has expanded the therapeutic landscape for CIC, offering patients more effective and targeted treatment options. These innovations not only improve bowel function but also address the underlying mechanisms of constipation, enhancing overall patient satisfaction. As research continues to explore new therapies and combination treatments, the chronic idiopathic constipation treatment market is likely to expand further, driven by the promise of improved patient care and quality of life.

Additionally, the growing emphasis on lifestyle modifications and preventive care is shaping the chronic idiopathic constipation treatment landscape. As healthcare providers increasingly recognize the importance of diet, hydration, and physical activity in managing CIC, the demand for educational resources and support programs is likely to increase. This proactive approach not only empowers patients to take control of their condition but also fosters a collaborative relationship between patients and healthcare providers. As the market continues to evolve, the combination of innovative therapies, patient education, and a focus on lifestyle interventions will play a crucial role in driving its future growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Normal-transit constipation
• Slow-transit constipation
• Others

By Therapy Type

• Pharmacological Therapy
• Non-pharmacological Therapy
• ByA Treatment Type
• Medication
• Surgery

By Drugs

• Serotonin-4 (5-Ht4) Receptor Agonist
• Guanylate Cyclase-C Agonist
• Laxatives
• Stimulants
• Others

By Route of Administration

• Oral
• Injectable

By End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others
• ByA Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• ALLERGAN, Mallinckrodt plc, Synergy Pharmaceuticals Inc, Shandong Luoxin Pharmaceutical Group Stock Co Ltd, Takeda Pharmaceutical Company Limited, Sanofi, Zydus Cadila, Boehringer Ingelheim International GmbH, Shreya Life Sciences Pvt Ltd, Abbott, GSK plc, Troikaa Pharmaceuticals Ltd, Lupin, East West Pharma, Ironwood Pharmaceuticals Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Normal-transit constipation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Slow-transit constipation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy Type
• 5.2. Pharmacological Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Non-pharmacological Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY TREATMENT TYPE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Treatment Type
• 6.2. Medication Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Surgery Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY DRUGS 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Drugs
• 7.2. Serotonin-4 (5-Ht4) Receptor Agonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Guanylate Cyclase-C Agonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Laxatives Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Stimulants Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Route Of Administration
• 8.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY END-USERS 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End-users
• 9.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Homecare Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. Specialty Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Distribution Channel
• 10.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET: BY REGION 2022-2034(USD MN)

• 11.1. Regional Outlook
• 11.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.2.1 By Type
  • 11.2.2 By Therapy Type
  • 11.2.3 By Treatment Type
  • 11.2.4 By Drugs
  • 11.2.5 By Route Of Administration
  • 11.2.6 By End-users
  • 11.2.7 By Distribution Channel
  • 11.2.8 United States
  • 11.2.9 Canada
  • 11.2.10 Mexico
• 11.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.3.1 By Type
  • 11.3.2 By Therapy Type
  • 11.3.3 By Treatment Type
  • 11.3.4 By Drugs
  • 11.3.5 By Route Of Administration
  • 11.3.6 By End-users
  • 11.3.7 By Distribution Channel
  • 11.3.8 United Kingdom
  • 11.3.9 France
  • 11.3.10 Germany
  • 11.3.11 Italy
  • 11.3.12 Russia
  • 11.3.13 Rest Of Europe
• 11.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.4.1 By Type
  • 11.4.2 By Therapy Type
  • 11.4.3 By Treatment Type
  • 11.4.4 By Drugs
  • 11.4.5 By Route Of Administration
  • 11.4.6 By End-users
  • 11.4.7 By Distribution Channel
  • 11.4.8 India
  • 11.4.9 Japan
  • 11.4.10 South Korea
  • 11.4.11 Australia
  • 11.4.12 South East Asia
  • 11.4.13 Rest Of Asia Pacific
• 11.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.5.1 By Type
  • 11.5.2 By Therapy Type
  • 11.5.3 By Treatment Type
  • 11.5.4 By Drugs
  • 11.5.5 By Route Of Administration
  • 11.5.6 By End-users
  • 11.5.7 By Distribution Channel
  • 11.5.8 Brazil
  • 11.5.9 Argentina
  • 11.5.10 Peru
  • 11.5.11 Chile
  • 11.5.12 South East Asia
  • 11.5.13 Rest of Latin America
• 11.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 11.6.1 By Type
  • 11.6.2 By Therapy Type
  • 11.6.3 By Treatment Type
  • 11.6.4 By Drugs
  • 11.6.5 By Route Of Administration
  • 11.6.6 By End-users
  • 11.6.7 By Distribution Channel
  • 11.6.8 Saudi Arabia
  • 11.6.9 UAE
  • 11.6.10 Israel
  • 11.6.11 South Africa
  • 11.6.12 Rest of the Middle East And Africa

Chapter 12. COMPETITIVE LANDSCAPE

• 12.1. Recent Developments
• 12.2. Company Categorization
• 12.3. Supply Chain & Channel Partners (based on availability)
• 12.4. Market Share & Positioning Analysis (based on availability)
• 12.5. Vendor Landscape (based on availability)
• 12.6. Strategy Mapping

Chapter 13. COMPANY PROFILES OF GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY

• 13.1. Top Companies Market Share Analysis
• 13.2. Company Profiles
  • 13.2.1 ALLERGAN
  • 13.2.2 Mallinckrodt Plc
  • 13.2.3 Synergy Pharmaceuticals Inc
  • 13.2.4 Shandong Luoxin Pharmaceutical Group Stock Co. Ltd
  • 13.2.5 Takeda Pharmaceutical Company Limited
  • 13.2.6 Sanofi
  • 13.2.7 Zydus Cadila
  • 13.2.8 Boehringer Ingelheim International GmbH
  • 13.2.9 Shreya Life Sciences Pvt Ltd
  • 13.2.10 Abbott
  • 13.2.11 GSK Plc
  • 13.2.12 Troikaa Pharmaceuticals Ltd
  • 13.2.13 Lupin
  • 13.2.14 East West Pharma
  • 13.2.15 Ironwood Pharmaceuticals Inc